Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's Under Fed Condition
Primary Purpose
Healthy
Status
Completed
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
Fluoxetine Hydrochloride
Sponsored by
About this trial
This is an interventional treatment trial for Healthy focused on measuring Bioequivalence, Crossover, Fluoxetine Hydrochloride
Eligibility Criteria
Inclusion Criteria:
- Healthy human subjects between 18-50 years of age (inclusive), weighing as per the standard height and weight chart of Life Insurance Corporation of India (11 Underweight and Overweight Min. & Max. Chart).
- Subjects who have no evidence of underlying disease during screening medical history and whose physical examination is performed within 21 days prior to commencement of the study.
- Subjects whose screening laboratory values are within normal limits or considered by the physician/Principal Investigator to be of no clinical significance.
- Informed consent given in written form according to section 11.3 of the protocol.
Female Subjects
- of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies,diaphragm, intrauterine device, or abstinence.
- postmenopausal for at least I year.
- surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)
Exclusion Criteria:
- Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
- Alcohol dependence, Alcohol abuse, i.e., regular use of more than 2 units of alcohol or 10 units per week or a history of alcoholism (one unit of alcohol equals 1/2 1 of beer 200 ml wine or 50 ml (of spirits) within last 6 months or recovered alcoholics , or drug abuse within past 1 year.
- Moderate to heavy smoking (> 10 cigarettes/day) or consumption of tobacco products.
- History of difficulty in swallowing capsules.
- Clinically significant illness within 4 weeks before the start of the study.
- Asthma, urticaria or other allergic type reactions after taking any medication.
- Positive urine drug screening, Human Immunodeficiency Virus, Hepatitis B & C tests.
- Any history of hypersensitivity to fluoxetine.
Sites / Locations
- Lotus Labs Private Limited
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Fluoxetine Hydrochloride
Prozac ® weekly
Arm Description
Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
Outcomes
Primary Outcome Measures
Bioequivalence based on Cmax and AUC parameters
Secondary Outcome Measures
Full Information
NCT ID
NCT01166087
First Posted
July 19, 2010
Last Updated
July 20, 2010
Sponsor
Dr. Reddy's Laboratories Limited
1. Study Identification
Unique Protocol Identification Number
NCT01166087
Brief Title
Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's Under Fed Condition
Official Title
A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's and Prozac®Weekly 90 mg Delayed Release Capsules of Eli Lilly and Company, USA in Healthy Adult Human Subjects Under Fed Conditions.
Study Type
Interventional
2. Study Status
Record Verification Date
July 2010
Overall Recruitment Status
Completed
Study Start Date
February 2006 (undefined)
Primary Completion Date
March 2006 (Actual)
Study Completion Date
September 2006 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Dr. Reddy's Laboratories Limited
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to asses the bioequivalence study of Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg and Prozac ® weekly under fed conditions.
Detailed Description
A randomized, open label, two treatment, two period, two sequence, single dose, crossover bioequivalence study of Fluoxetine Hydrochloride Delayed-Release capsules 90 mg of Dr. Reddy's laboratories limited, Generics, India and Prozac®weekly 90 mg delayed release capsules of Eli Lilly and company, USA in healthy adult human subjects under fed conditions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy
Keywords
Bioequivalence, Crossover, Fluoxetine Hydrochloride
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
54 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Fluoxetine Hydrochloride
Arm Type
Experimental
Arm Description
Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
Arm Title
Prozac ® weekly
Arm Type
Active Comparator
Arm Description
Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
Intervention Type
Drug
Intervention Name(s)
Fluoxetine Hydrochloride
Other Intervention Name(s)
Prozac ® weekly 90 mg Delayed Release Capsules
Intervention Description
Fluoxetine Hydrocloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories.
Primary Outcome Measure Information:
Title
Bioequivalence based on Cmax and AUC parameters
Time Frame
8 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy human subjects between 18-50 years of age (inclusive), weighing as per the standard height and weight chart of Life Insurance Corporation of India (11 Underweight and Overweight Min. & Max. Chart).
Subjects who have no evidence of underlying disease during screening medical history and whose physical examination is performed within 21 days prior to commencement of the study.
Subjects whose screening laboratory values are within normal limits or considered by the physician/Principal Investigator to be of no clinical significance.
Informed consent given in written form according to section 11.3 of the protocol.
Female Subjects
of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies,diaphragm, intrauterine device, or abstinence.
postmenopausal for at least I year.
surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)
Exclusion Criteria:
Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
Alcohol dependence, Alcohol abuse, i.e., regular use of more than 2 units of alcohol or 10 units per week or a history of alcoholism (one unit of alcohol equals 1/2 1 of beer 200 ml wine or 50 ml (of spirits) within last 6 months or recovered alcoholics , or drug abuse within past 1 year.
Moderate to heavy smoking (> 10 cigarettes/day) or consumption of tobacco products.
History of difficulty in swallowing capsules.
Clinically significant illness within 4 weeks before the start of the study.
Asthma, urticaria or other allergic type reactions after taking any medication.
Positive urine drug screening, Human Immunodeficiency Virus, Hepatitis B & C tests.
Any history of hypersensitivity to fluoxetine.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr. James John, MBBS, MD
Organizational Affiliation
Lotus Labs Private Limited
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lotus Labs Private Limited
City
Mylapore
State/Province
Chennai
ZIP/Postal Code
600 004
Country
India
12. IPD Sharing Statement
Learn more about this trial
Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's Under Fed Condition
We'll reach out to this number within 24 hrs